RALEIGH, N.C., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced the publication of two clinical studies focused on two of its core technologies: the AxiaLIF® Plus presacral access and interbody fusion system and the iO-Flex® minimally invasive decompression instrument. Both studies are featured in the December 1st edition of the Journal of Spinal Disorders and Techniques.
"Having two of our core technologies represented in the December issue of JSDT is certainly an honor," commented Ken Reali, President and CEO Baxano Surgical. "This positive clinical data on Baxano Surgical's unique technologies adds to our growing compendium of peer-reviewed publications and validates our continued efforts in expanding our clinical strategy to advance our minimally invasive spine implants and instruments."
The first paper describes a head-to-head study by two independent spine surgeons comparing AxiaLIF Plus to ALIF in 96 total patients. AxiaLIF Plus 1-Level (L5-S1) with pedicular fixation was compared to ALIF (L5-S1) with pedicular fixation and was authored by Peter G. Whang, MD. All patients had two year or greater follow up with thin slice CT scans.
In the surgeons' combined review, AxiaLIF Plus demonstrated higher fusion rates than ALIF, although the difference was not statistically significant. Further, the AxiaLIF cohort experienced no serious adverse events, compared with the ALIF cohort, in which one serious adverse event was reported.
"Based upon our clinical and radiographic review, the safety and efficacy of the AxiaLIF procedure appears to be comparable to that of ALIF when used in conjunction with posterior instrumentation, suggesting that this less invasive technique is a viable method for achieving an interbody fusion across the lumbosacral junction," commented Dr. Peter Whang, Associate Professor of Orthopaedics and Rehabilitation at Yale University.
The second paper describes data from a prospective, observational study on 59 subjects who underwent a facet-sparing decompression using the iO-Flex minimally invasive decompression instrument for lumbar spinal stenosis. Operative technique, operative data and surgical adverse events were evaluated. With the iO-Flex instrument there were no device-related operative complications. A subset of patients were evaluated radiographically using CT scans, access to the lateral recess and foramen was achieved with removal of less than 6% of the superior facet cross-sectional area. The study was authored by Lawrence M. Dickinson, MD.
"We have shown that the iO-Flex instrument coupled with standard surgical technique comprehensively decompresses the central canal, lateral recess and far lateral foramen while preserving the facet anatomy, thus limiting the cause of future instability. Symptom resolution, including back pain has been very impressive. The fact that iO-Flex preserves the posterior anatomy should result in a much lower incidence of instability and reoperation rate," stated Dr. Lawrence Dickinson from Pacific Brain and Spine.
About Baxano Surgical, Inc.
Baxano Surgical, Inc. is a medical device company focused on designing, developing, and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. Baxano Surgical currently markets the AxiaLIF® family of products for single and two level lower lumbar fusion, the VEO® lateral access and interbody fusion system, the iO-Flex® system, a proprietary set of flexible instruments used by surgeons during spinal decompression procedures and the iO-Tome® instrument, which rapidly and precisely removes bone, specifically the facet joints, which is commonly performed in spinal fusion procedures. Baxano Surgical was founded in May 2000 and is headquartered in Raleigh, North Carolina. For more information, visit www.baxanosurgical.com.
AxiaLIF, VEO, iO-Flex and iO-Tome are registered trademarks of Baxano Surgical.
CONTACT: Westwicke Partners Mark Klausner 443-213-0501 email@example.comSource:Baxano Surgical, Inc.